{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:37:55Z","timestamp":1785188275885,"version":"3.55.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"am","delay-in-days":356,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.eururo.2020.04.039","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T01:54:37Z","timestamp":1587693277000},"page":"1-3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Adjustments in the Use of Intravesical Instillations of Bacillus Calmette-Gu\u00e9rin for High-risk Non-muscle-invasive Bladder Cancer During the COVID-19 Pandemic"],"prefix":"10.1016","volume":"78","author":[{"given":"Louis","family":"Lenfant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2020.04.039_bib0005","series-title":"Cancer Facts & Figures 2020","author":"American Cancer Society","year":"2020"},{"key":"10.1016\/j.eururo.2020.04.039_bib0010","doi-asserted-by":"crossref","unstructured":"Guan W.J., Ni Z.Y., Hu Y., et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. In press. https:\/\/doi.org\/10.1056\/NEJMoa2002032.","DOI":"10.1056\/NEJMoa2002032"},{"key":"10.1016\/j.eururo.2020.04.039_bib0015","article-title":"Intravesical bacillus Calmette-Guerin in Ta and T1 bladder cancer","volume":"2000","author":"Shelley","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2020.04.039_bib0020","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.04.039_bib0025","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology guidelines on non\u2013muscle-invasive bladder cancer (TaT1 and carcinoma in situ) \u2013 2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.04.039_bib0030","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.04.039_bib0035","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.04.039_bib0040","unstructured":"Miller A., Reandelar M.J., Fasciglione K., et al. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv preprint. www.medrxiv.org\/content\/10.1101\/2020.03.24.20042937v1."},{"key":"10.1016\/j.eururo.2020.04.039_bib0045","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1128\/JVI.02393-08","article-title":"CD4 T-cell-mediated heterologous immunity between mycobacteria and poxviruses","volume":"83","author":"Mathurin","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.eururo.2020.04.039_bib0050","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2020.04.039_bib0055","doi-asserted-by":"crossref","first-page":"m1185","DOI":"10.1136\/bmj.m1185","article-title":"Non-steroidal anti-inflammatory drugs and covid-19","volume":"368","author":"Little","year":"2020","journal-title":"BMJ"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382030302X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382030302X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:07:19Z","timestamp":1759583239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228382030302X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S030228382030302X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2020.04.039","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjustments in the Use of Intravesical Instillations of Bacillus Calmette-Gu\u00e9rin for High-risk Non-muscle-invasive Bladder Cancer During the COVID-19 Pandemic","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2020.04.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}